RecruitingNot ApplicableNCT06230861

Effects of Quercetin on Cardiometabolic Outcomes

Effects of Quercetin Supplementation on Cardiometabolic Parameters


Sponsor

University of Central Lancashire

Enrollment

40 participants

Start Date

Mar 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and Quercetin for people with cardiometabolic syndrome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTQuercetin

Quercetin tablets 500mg 1 x per day

OTHERPlacebo

Placebo control 1 x blinded placebo tablet per day


Locations(1)

University of Central Lancashire

Preston, Lancashire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06230861


Related Trials